YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Regeneron Pharmaceuticals Inc — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.02, while Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none. Which is the better fit depends on your goals.
| QDTY | REGN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $812.27 |
52-Week Low | $36.57 | $545.46 |
Market Cap | — | $70.79B |
Enterprise Value | — | $64.74B |
Dividend Yield | — | 0.56% |
Signals from Pluang's Aura AI — not financial advice
QDTY trades at $39.53 with minimal daily movement (+0.15%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, while oscillators remain neutral. The stock faces immediate resistance at $40 and support at $39. Recent corporate actions include consistent weekly dividend distributions, with amounts ranging from $0.22 to $0.32 per share throughout 2026.
The outlook remains cautious given the bearish technical signals and lack of available fundamental data. While the consistent dividend payments provide some income stability, the absence of key financial metrics like P/E ratio and profitability measures limits fundamental analysis. Investors face uncertainty regarding the company's financial health and growth prospects without current earnings data.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Trailing returns across standard periods
Latest headlines on both assets
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →